About
Technology
Issues
FAQ
Links
Official Page
Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.